Data from PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma

• DOI: 10.1158/1078-0432.c.6523421.v1
• Publication Date: 2023-04-01T06:41:07Z
• Authors: Matthew G. Field; Christina L. Decatur; Stefan Kurtenbach; Gülçin Gezgin; Pieter A. van der...; Martine J. Jager; Kaleigh N. Kozak; J. William Harbour
• Keywords: BAP1

<div>Abstract<p><b>Purpose:</b> Uveal melanoma (UM) can be classified by gene expression profiling (GEP) into Class 1 (low metastatic risk) and 2 (high risk), the latter being strongly associated with mutational inactivation of tumor suppressor BAP1. Nevertheless, a small percentage tumors give rise to disease. The purpose this study was identify biomarkers metastasis in tumors.</p><p><b>Experimental Design:</b> A total 389 consecutive patients UM were assigned or using prospectively validated 12-gene prognostic classifier. Selected further analyzed global GEP single nucleotide polymorphism microarrays. <i>PRAME</i> (preferentially expressed antigen melanoma) mRNA 64 qPCR.</p><p><b>Results:</b> Among UMs, most significant predictor (<i>P</i> = 0.0006). 5-year actuarial rate 0% for Class1<sup>PRAME−</sup>, 38% Class1<sup>PRAME+</sup>, 71% tumors. Median metastasis-free survival Class1<sup>PRAME+</sup> 88 months, compared 32 months patients. Findings three independent datasets, including one disomy 3 low-risk UM. Chromosome copy number changes included gain 1q, 6p, 8q, 9q loss 6q 11q. larger diameter 0.05) <i>SF3B1</i> mutations 0.003).</p><p><b>Conclusions:</b> is an biomarker UM, which identifies increased risk This finding may enhance accuracy testing precision medicine <i>Clin Cancer Res; 22(5); 1234–42. ©2016 AACR</i>.</p></div>